Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taiwan.
Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taiwan.
J Formos Med Assoc. 2022 Mar;121(3):643-651. doi: 10.1016/j.jfma.2021.06.015. Epub 2021 Jul 8.
BACKGROUND/PURPOSE: Decorin is a small leucine-rich proteoglycan rich in extracellular matrix with potential antitumor activity. However, the role of decorin in hematological malignancies remains unclear, especially in the case of multiple myeloma (MM), a bone marrow (BM) stroma-dependent plasma cell neoplasm.
We measured decorin levels in BM plasma samples from 270 patients with newly diagnosed MM (NDMM) using enzyme-linked immunosorbent assays.
Patients were divided into high decorin (H-DCN, > 18.99 ng/mL) and low decorin (L-DCN <9.76 ng/mL) groups. Patients in the H-DCN group had more advanced-stage disease, including more osteolysis terms of higher levels of C-terminal telopeptides of type I collagen (0.69 ± 0.55 vs. 0.49 ± 0.36 ng/mL; P = 0.028), than those in the L-DCN group. Decorin levels correlated positively with hepatocyte growth factor (HGF) levels in BM plasma samples from NDMM patients (Pearson correlation coefficient, 0.226; P < 0.001). Patients with low HGF (<0.79 ng/mL) but high decorin levels (≥12.95 ng/mL) had a higher treatment response rate (90.5% vs. 54.5%, respectively; P = 0.015) and improved overall survival (not reached vs. 53 months; P = 0.0148) than those with lower decorin levels (<12.95 ng/mL). Multivariate analysis confirmed that a high decorin level was an independent predictive factor for treatment response and survival in patients with low HGF levels.
Our findings suggest that decorin may exert protective effects in this subset of MM patients.
背景/目的：核心蛋白聚糖（decorin）是富含细胞外基质的富含亮氨酸的小蛋白聚糖，具有潜在的抗肿瘤活性。然而，decorin 在血液恶性肿瘤中的作用尚不清楚，特别是在骨髓（BM）基质依赖性浆细胞瘤多发性骨髓瘤（MM）中。
我们使用酶联免疫吸附试验测量了 270 例初诊 MM（NDMM）患者 BM 血浆样本中的 decorin 水平。
患者分为高 decorin（H-DCN，>18.99ng/mL）和低 decorin（L-DCN <9.76ng/mL）组。H-DCN 组患者疾病分期更晚，包括更高水平的Ⅰ型胶原 C 端肽（0.69±0.55 vs. 0.49±0.36ng/mL；P=0.028）和更多的溶骨性术语。HGF 水平与 NDMM 患者 BM 血浆样本中的 decorin 水平呈正相关（Pearson 相关系数，0.226；P<0.001）。HGF 水平低（<0.79ng/mL）但 decorin 水平高（≥12.95ng/mL）的患者治疗反应率（90.5% vs. 54.5%，分别；P=0.015）和总生存率（未达到 vs. 53 个月；P=0.0148）均较高，而 decorin 水平较低（<12.95ng/mL）的患者则较低。多变量分析证实，高 decorin 水平是 HGF 水平低的患者治疗反应和生存的独立预测因素。
我们的研究结果表明，decorin 可能对这部分 MM 患者发挥保护作用。
